Treatment of TTP/HUS
Reading File
Finding Sources
Finding Sources
Searching PubMed
"thrombotic thrombocytopenic purpura" AND treatment
Searching PubMed
"hemolytic uremic syndrome" AND treatment
Searching the Web
ISTH guidelines immune thrombotic thrombocytopenic purpura treatment caplacizumab plasma exchange corticosteroids 2025
Reading File
Reading File
Finding Sources
Reading Web Page
https://www.isth.org/page/ttpguidelines
Treatment of TTP and HUS
Both are thrombotic microangiopathies with thrombocytopenia and microangiopathic hemolytic anemia. They must be distinguished because treatment differs substantially.
1. Suspected TTP: treat as a hematologic emergency
If TTP is clinically likely, draw blood for ADAMTS13 activity and inhibitor before plasma treatment if possible, but do not wait for the result.
| Treatment | Role |
|---|---|
| Urgent daily therapeutic plasma exchange (TPE/PLEX) with plasma replacement | Main immediate treatment for immune-mediated TTP. Removes anti-ADAMTS13 antibodies and supplies ADAMTS13. Continue daily until platelet count and hemolysis have normalized, then stop according to specialist protocol. |
| Corticosteroids | Give with PLEX in immune TTP, commonly high-dose glucocorticoid therapy. |
| Caplacizumab | Add early in immune-mediated TTP, where available. It blocks platelet-VWF interaction and reduces ongoing microvascular thrombosis. It increases bleeding risk. |
| Rituximab | Early addition is often used in immune TTP, particularly severe disease, slow response, exacerbation/relapse, or high anti-ADAMTS13 antibody burden. |
| Supportive care | ICU-level monitoring if neurologic/cardiac involvement, red-cell transfusion as needed, dialysis if needed, and treatment of triggers such as infection. |
| Avoid platelet transfusion | Avoid routinely because it may worsen thrombosis. Use only for life-threatening bleeding or an essential invasive procedure, with hematology input. |
Congenital TTP (Upshaw-Schulman syndrome): ADAMTS13 replacement with plasma infusion or recombinant ADAMTS13 where available. It requires prophylaxis during high-risk periods such as pregnancy or recurrent episodes. The 2025 ISTH update favors prophylactic fresh frozen plasma rather than observation alone during remission in congenital TTP. See the ISTH TTP guidance.
Plasma exchange transformed TTP outcomes and should never be delayed solely pending ADAMTS13 testing. Harrison's Principles of Internal Medicine, 22e, p. 968.
2. Typical HUS: Shiga toxin-producing E. coli (STEC-HUS), usually after bloody diarrhea
Treatment is mainly supportive:
- Careful fluid and electrolyte management.
- Treat hypertension.
- Red-cell transfusion for symptomatic/severe anemia.
- Dialysis for acute kidney injury with standard indications: refractory hyperkalemia, severe acidosis, fluid overload, uremic complications, or persistent oliguria/anuria.
- Monitor neurologic complications, particularly in severe adult disease.
- Avoid antimotility agents.
- Do not routinely use antibiotics for suspected/confirmed STEC infection unless there is another compelling indication, because bacterial lysis and toxin release may worsen HUS risk. Discuss with infectious-disease/renal specialists in severe or atypical situations.
- Plasma exchange, steroids, and caplacizumab are not routine treatment for typical STEC-HUS.
3. Atypical HUS: complement-mediated HUS
This is a complement dysregulation disorder and needs urgent nephrology and hematology involvement.
| Treatment | Role |
|---|---|
| C5 complement inhibition: eculizumab or ravulizumab | First-line disease-specific treatment for complement-mediated aHUS. Start promptly once TTP and other secondary thrombotic microangiopathies are being excluded. |
| Meningococcal protection | Give meningococcal vaccination before treatment when feasible. If treatment cannot wait, start appropriate antibiotic prophylaxis as per local protocol because terminal complement blockade markedly raises meningococcal infection risk. |
| Supportive renal care | Blood-pressure control, dialysis if required, transfusion support, and management of complications. |
| Plasma exchange | May be started temporarily if TTP cannot initially be excluded or when complement therapy is unavailable, but is not the preferred definitive therapy for complement-mediated aHUS. |
| Treat precipitating factors | Infection, pregnancy/postpartum state, hypertension, transplantation, or certain drugs may trigger disease. |
High-yield distinction
- TTP: severe ADAMTS13 deficiency, often neurologic features. Treat immediately with PLEX + steroids + caplacizumab, usually with rituximab.
- STEC-HUS: diarrheal prodrome and predominant AKI. Treat supportively.
- Complement-mediated aHUS: complement dysregulation. Treat with eculizumab or ravulizumab plus infection prevention and renal support.
Recent evidence may refine practical decisions about plasma products, caplacizumab, recombinant ADAMTS13, and duration of complement inhibition. Relevant recent systematic reviews include PMIDs 41934124, 39644810, 41838094, and 40795230.
This is a shared conversation. Sign in to Orris to start your own chat.